Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-finding study of inecalcitol with docetaxel and prednisone in hormone-refractory prostate cancer
2007-002702-21Phase 2Active
- Sponsor
- Hybrigenics
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inecalcitol in castration-resistant prostate cancer (CRPC) and Metastatic Prostate Cancer (mPC), sponsored by Hybrigenics. Primary endpoints: Blood calcium level and Maximum tolerated dose. Started Jul 2007; status: active.
02
Drugs
inecalcitol
03
Conditions
castration-resistant prostate cancer (CRPC)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on 2007-002702-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002702-21.